National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2015 (No. 4) (PB 44 of 2015)

Link to law: https://www.comlaw.gov.au/Details/F2015L00604

 
PB 44 of 2015
National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2015 (No. 4)
 
National Health Act 1953
___________________________________________________________________________
 
I, Tony Wynd, A/g Assistant Secretary, Pharmaceutical Access Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.
 
Dated     24 April 2015
 
 
 
 
 
 
 
 
 
 
 
 
TONY WYND
A/g Assistant Secretary
Pharmaceutical Access Branch       
Pharmaceutical Benefits Division
Department of Health
 
___________________________________________________________________
1              Name of Instrument
 
(1)                This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2015 (No.4).
 
(2)                This Instrument may also be cited as PB 44 of 2015.
2             Commencement
                This Instrument commences on 1 May 2015.
3              Amendments to PB 79 of 2011
                      Schedule 1 amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).
 
 
Schedule 1                   Amendments
 
[1]     Schedule 1 Part 1 entry for ‘Doxorubicin’ in the form ‘Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 10 mg in 5 mL single dose vial’ and manner of administration ‘Injection/intravesical’:
substitute:
Doxorubicin
Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 10 mg in 5 mL single dose vial
Injection/ intravesical
Doxorubicin SZ
HX
MP
 
D

 
 
 
Hospira Pty Limited
HH
MP
 
D

[2]     Schedule 1 Part 1 entry for ‘Fludarabine’ in the form ‘Powder for I.V. injection containing fludarabine phosphate 50 mg’ and manner of administration ‘Injection’:
substitute:
Fludarabine
Powder for I.V. injection containing fludarabine phosphate 50 mg
Injection
Fludara
GZ
MP
C3887
PB
[3]     Schedule 1 Part 1 entry for ‘Irinotecan’ in the form ‘I.V injection containing irinotecan hydrochloride trihydrate 100 mg in 5 mL’ and manner of administration ‘Injection’:
omit:
Irinotecan Actavis
UA
MP
 
D

Tecan
GN
MP
 
D

[4]     Schedule 1 Part 1 entry for ‘Irinotecan’ in the form ‘I.V injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL’ and manner of administration ‘Injection’:
omit:
Tecan
GN
MP
 
D
[5]     Schedule 1 Part 1 entry for ‘Oxaliplatin’ in each of the forms ‘Powder for I.V. infusion 100 mg’ and ‘Powder for I.V. infusion 50 mg’ and manner of administration ‘Injection’:
omit:
Oxaliplatin Actavis
UA
MP
 
D
 
[6]     Schedule 1 Part 1 entry for ‘Oxaliplatin’ in the form ‘Solution concentrate for I.V. infusion 50 mg in 10 mL’ and manner of administration ‘Injection’:
omit:
Oxaliccord
GN
MP
 
D
 
Read Entire Law on www.comlaw.gov.au